At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 264 enrolled
Drug / intervention
lanreotide (Autogel formulation) +1 moredrug
Likely dose
lanreotide (Autogel formulation) 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour
In Brief
A Phase 3 clinical trial evaluating lanreotide (Autogel formulation) and Placebo for Endocrine Tumors. Completed, enrolled 264 participants across 71 sites in 15 countries.
Detailed Summary
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndocrine Tumors
CountriesAustria, Belgium, Czechia, Denmark, France, Germany, India, Italy, Netherlands, Poland, Slovakia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJul 2006
Primary CompletionApr 2013
TodayJul 2026
First PostedJul 18, 2006
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.0 years ago
Interventions
lanreotide (Autogel formulation)drug
120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Placebodrug
Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.